Table 1.
Baseline demographic and clinical variables
| Variables | Cases | Controls |
|---|---|---|
| n | 128 | 43 |
| Female | 96% | 100% |
| Age, years | 55 ± 10 | 51 ± 10* |
| BMI, kg/m2 | 29.3 ± 7.6 | 25.6 ± 3.7* |
| Race (non-Caucasian) | 31 (24.2%) | 17 (39.5%) |
| Tobacco use | ||
| Current | 2 (1.6%) | 2 (4.7%) |
| Former | 38 (29.7%) | 13 (30.2%) |
| Never | 88(68.8%% | 27 (62.8) |
| History of Hypertension | 69 (53.9%) | 0 |
| History of Diabetes | 23 (18.0%) | 0 |
| History of Hyperlipidaemia | 70 (54.7%) | 1 (2.3%) |
| Family history of premature coronary artery disease |
83 (64.8%) | 13 (30.2%) |
| LV Ejection Fraction, % | 68 ± 8 | 65 ± 6* |
| Heart rate, bpm | 67 ± 12 | 64 ± 11 |
| Systolic Blood Pressure, mmHg | 128 ± 20 | 119 ± 14* |
| Diastolic Blood Pressure, mmHg | 62 ± 13 | 66 ± 9* |
| Medications | ||
| Beta-blockers | 54 (42.2%) | 0 |
| Calcium Channel blockers | 29 (22.7%) | 0 |
| Angiotensin-converting enzyme inhibitors | 13 (10.2%) | 0 |
| Nitrates | 50 (39.1%) | 0 |
| Statins | 74 (57.8%) | 0 |
| Hormone replacement Therapy | 16 (12.5%) | 0 |
Mean ± SD or absolute frequency (%).
*
indicates P < 0.05